RxDoctor Payments Data

David Watkins

Medical Oncology · Midland, TXNPI 1770526642

Payments from drug & device makers

What this record shows

7 manufacturers reported payments, led by Johnson & Johnson at 49.5% of the total. Reporting peaked in 2020 at $186 and has fallen 67.2% since, to $61 in 2022. That places this record below the midpoint for medical oncology clinicians in TX, where the typical reported total is $4,372.

$323in general payments, 2019–2025

Across 8 payments — averaging $40.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$160
  • AstraZeneca$57
  • E.r. Squibb & Sons, L.L.C.$30
  • Jazz Pharmaceuticals Inc.$22
  • Lilly USA, LLC$22
  • Pharmacyclics LLC, An Abbvie Company$20
  • plus $12 from 1 others
$511,501in research payments, 2019–2025

Across 343 payments — averaging $1491.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$217K
  • E.r. Squibb & Sons, L.L.C.$116K
  • Incyte Corporation$109K
  • Janssen Research & Development, LLC$46K
  • Eli Lilly$15K
  • Pharmacyclics LLC, An Abbvie Company$7K
  • plus $1K from 2 others

What the payments were for

  • Food & beverage$15147%
  • Education$17253%

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$323 in reported general payments places this provider in the 15th percentile of 495 medical oncology providers in Texas.

See all medical oncology providers in Texas →

Other medical oncology in Midland

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →